{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:23:37Z","timestamp":1788877417658,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Microbiome-based therapies for inflammatory bowel diseases offer a novel and promising therapeutic approach. The human commensal bacteria of the species <jats:italic>Christensenella minuta<\/jats:italic> (<jats:italic>C. minuta<\/jats:italic>) have been reported consistently missing in patients affected by Crohn\u2019s disease (CD) and have been documented to induce anti-inflammatory effects in human epithelial cells, supporting their potential as a novel biotherapy. This work aimed at selecting the most promising strain of <jats:italic>C. minuta<\/jats:italic> for future development as a clinical candidate for CD therapy. Here, we describe a complete screening process combining in vitro and in vivo assays to conduct a rational selection of a live strain of <jats:italic>C. minuta<\/jats:italic> with strong immunomodulatory properties. Starting from a collection of 32 strains, a panel of in vitro screening assays was used to narrow it down to five preclinical candidates that were further screened in vivo in an acute TNBS-induced rat colitis model. The most promising candidate was validated in vivo in two mouse models of colitis. The validated clinical candidate strain, <jats:italic>C. minuta<\/jats:italic> DSM 33715, was then fully characterized. Hence, applying a rationally designed screening algorithm, a novel strain of <jats:italic>C. minuta<\/jats:italic> was successfully identified as the most promising clinical candidate for CD.<\/jats:p>","DOI":"10.1038\/s41598-022-10015-3","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T09:02:47Z","timestamp":1649667767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Selection of a novel strain of Christensenella minuta as a future biotherapy for Crohn\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Karima","family":"Relizani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Le Corf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Kropp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Martin-Rosique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9borah","family":"Kissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"D\u00e9jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ccori","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Rawadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Elustondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfrid","family":"Mazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine P.","family":"Claus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"10015_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.pop.2017.07.010","volume":"44","author":"T Sairenji","year":"2017","unstructured":"Sairenji, T., Collins, K. L. & Evans, D. V. An update on inflammatory bowel disease. Prim. Care Clin. Off. Pract. 44, 673\u2013692 (2017).","journal-title":"Prim. Care Clin. Off. Pract."},{"key":"10015_CR2","doi-asserted-by":"publisher","first-page":"13780","DOI":"10.1073\/pnas.0706625104","volume":"104","author":"DN Frank","year":"2007","unstructured":"Frank, D. N. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. 104, 13780\u201313785 (2007).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10015_CR3","first-page":"1","volume":"20","author":"T Braun","year":"2019","unstructured":"Braun, T. et al. Individualized dynamics in the gut microbiota precede Crohn\u02bcs disease flares. Am. J. Gastroenterol. 20, 1\u201310 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"10015_CR4","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1038\/s41467-021-23460-x","volume":"12","author":"D van der Lelie","year":"2021","unstructured":"van der Lelie, D. et al. Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis. Nat. Commun. 12, 3105 (2021).","journal-title":"Nat. Commun."},{"key":"10015_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1099\/ijs.0.026989-0","volume":"62","author":"M Morotomi","year":"2012","unstructured":"Morotomi, M., Nagai, F. & Watanabe, Y. Description of Christensenella minuta gen. nov., sp. nov., isolated from human faeces, which forms a distinct branch in the order Clostridiales, and proposal of Christensenellaceae fam. nov. Int. J. Syst. Evol. Microbiol. 62, 144\u2013149 (2012).","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"10015_CR6","doi-asserted-by":"publisher","first-page":"e01451","DOI":"10.1128\/genomeA.01451-16","volume":"5","author":"BA Rosa","year":"2017","unstructured":"Rosa, B. A., Hallsworth-Pepin, K., Martin, J., Wollam, A. & Mitreva, M. Genome sequence of Christensenella minuta DSM 22607 T. Genome Announc. 5, e01451-e1516 (2017).","journal-title":"Genome Announc."},{"key":"10015_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/gutjnl-2016-313235","volume":"66","author":"V Pascal","year":"2017","unstructured":"Pascal, V. et al. A microbial signature for Crohn\u2019s disease. Gut 66, 813\u2013822 (2017).","journal-title":"Gut"},{"key":"10015_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/gutjnl-2016-312135","volume":"67","author":"F Imhann","year":"2018","unstructured":"Imhann, F. et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 67, 108\u2013119 (2018).","journal-title":"Gut"},{"key":"10015_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/ibd\/izx061","volume":"24","author":"NA Kennedy","year":"2018","unstructured":"Kennedy, N. A. et al. The impact of NOD2 variants on fecal microbiota in Crohn\u2019s disease and controls without gastrointestinal disease. Inflamm. Bowel Dis. 24, 583\u2013592 (2018).","journal-title":"Inflamm. Bowel Dis."},{"key":"10015_CR10","first-page":"1","volume":"20","author":"M Zakrzewski","year":"2018","unstructured":"Zakrzewski, M. et al. IL23R-protective coding variant promotes beneficial bacteria and diversity in the ileal microbiome in healthy individuals without inflammatory bowel disease. J. Crohns Colitis 20, 1\u201335 (2018).","journal-title":"J. Crohns Colitis"},{"key":"10015_CR11","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1053\/j.gastro.2019.11.294","volume":"158","author":"R Pittayanon","year":"2020","unstructured":"Pittayanon, R. et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: A systematic review. Gastroenterology 158, 930\u2013946 (2020).","journal-title":"Gastroenterology"},{"key":"10015_CR12","doi-asserted-by":"publisher","first-page":"11494","DOI":"10.1038\/s41598-021-90885-1","volume":"11","author":"C Kropp","year":"2021","unstructured":"Kropp, C. et al. The Keystone commensal bacterium Christensenella minuta DSM 22607 displays anti-inflammatory properties both in vitro and in vivo. Sci. Rep. 11, 11494 (2021).","journal-title":"Sci. Rep."},{"key":"10015_CR13","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/0016-5085(95)90599-5","volume":"109","author":"CO Elson","year":"1995","unstructured":"Elson, C. O., Sartor, R. B., Tennyson, G. S. & Riddell, R. H. Experimental models of inflammatory bowel disease. Gastroenterology 109, 1344\u20131367 (1995).","journal-title":"Gastroenterology"},{"key":"10015_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/0016-5085(92)91779-4","volume":"102","author":"JL Wallace","year":"1992","unstructured":"Wallace, J. L., Keenan, C. M., Gale, D. & Shoupe, T. S. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology 102, 18\u201327 (1992).","journal-title":"Gastroenterology"},{"key":"10015_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/gut.41.4.487","volume":"41","author":"CK Ameho","year":"1997","unstructured":"Ameho, C. K. et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 41, 487\u2013493 (1997).","journal-title":"Gut"},{"key":"10015_CR16","first-page":"238","volume":"69","author":"HS Cooper","year":"1993","unstructured":"Cooper, H. S., Murthy, S. N., Shah, R. S. & Sedergran, D. J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69, 238\u2013249 (1993).","journal-title":"Lab. Invest."},{"key":"10015_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1365-2249.1998.00728.x","volume":"114","author":"LA Dieleman","year":"1998","unstructured":"Dieleman, L. A. et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 114, 385\u2013391 (1998).","journal-title":"Clin. Exp. Immunol."},{"key":"10015_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/cells10040823","volume":"10","author":"W Mazier","year":"2021","unstructured":"Mazier, W. et al. A new strain of Christensenella minuta as a potential biotherapy for obesity and associated metabolic diseases. Cells 10, 823 (2021).","journal-title":"Cells"},{"key":"10015_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/microorganisms9030565","volume":"9","author":"B Cuffaro","year":"2021","unstructured":"Cuffaro, B. et al. Identification of new potential biotherapeutics from human gut microbiota-derived bacteria. Microorganisms 9, 565 (2021).","journal-title":"Microorganisms"},{"key":"10015_CR20","first-page":"113","volume-title":"The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models","author":"D Martinez-Maqueda","year":"2015","unstructured":"Martinez-Maqueda, D., Miralles, B. & Recio, I. In The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models (eds Verhoeckx, K. et al.) 113\u2013124 (Springer, 2015)."},{"key":"10015_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/MIB.0000000000000264","volume":"21","author":"BS Boland","year":"2015","unstructured":"Boland, B. S. et al. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn\u2019s disease. Inflamm. Bowel Dis. 21, 323\u2013330 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"10015_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fmed.2019.00251","volume":"6","author":"AR Bourgonje","year":"2019","unstructured":"Bourgonje, A. R. et al. A combined set of four serum inflammatory biomarkers reliably predicts endoscopic disease activity in inflammatory bowel disease. Front. Med. (Lausanne) 6, 251 (2019).","journal-title":"Front. Med. (Lausanne)"},{"key":"10015_CR23","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/0016-5085(95)90692-4","volume":"108","author":"S Schreiber","year":"1995","unstructured":"Schreiber, S., Heinig, T., Thiele, H.-G. & Raedler, A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108, 1434\u20131444 (1995).","journal-title":"Gastroenterology"},{"key":"10015_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-P","volume":"75","author":"R K\u00fchn","year":"1993","unstructured":"K\u00fchn, R., L\u00f6hler, J., Rennick, D., Rajewsky, K. & M\u00fcller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263\u2013274 (1993).","journal-title":"Cell"},{"key":"10015_CR25","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.3748\/wjg.v23.i33.6016","volume":"23","author":"DD Eichele","year":"2017","unstructured":"Eichele, D. D. & Kharbanda, K. K. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J. Gastroenterol. 23, 6016\u20136029 (2017).","journal-title":"World J. Gastroenterol."},{"key":"10015_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00228-012-1389-0","volume":"69","author":"D Lacruz-Guzm\u00e1n","year":"2013","unstructured":"Lacruz-Guzm\u00e1n, D. et al. Influence of polymorphisms and TNF and IL1\u03b2 serum concentration on the infliximab response in Crohn\u2019s disease and ulcerative colitis. Eur. J. Clin. Pharmacol. 69, 431\u2013438 (2013).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10015_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4196\/kjpp.2014.18.4.279","volume":"18","author":"PK Randhawa","year":"2014","unstructured":"Randhawa, P. K., Singh, K., Singh, N. & Jaggi, A. S. A review on chemical-induced inflammatory bowel disease models in rodents. Korean J. Physiol. Pharmacol. 18, 279\u2013288 (2014).","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"10015_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/1056-8719(95)00001-X","volume":"33","author":"JL Wallace","year":"1995","unstructured":"Wallace, J. L., Le, T., Carter, L., Appleyard, C. B. & Beck, P. L. Hapten-induced chronic colitis in the rat: Alternatives to trinitrobenzene sulfonic acid. J. Pharmacol. Toxicol. Methods 33, 237\u2013239 (1995).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10015_CR29","doi-asserted-by":"publisher","first-page":"e54543","DOI":"10.1371\/journal.pone.0054543","volume":"8","author":"\u00d8 Brenna","year":"2013","unstructured":"Brenna, \u00d8. et al. Relevance of TNBS-colitis in rats: A methodological study with endoscopic, histologic and transcriptomic characterization and correlation to IBD. PLoS\u00a0One 8, e54543 (2013).","journal-title":"PLoS\u00a0One"},{"key":"10015_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ibd.20753","volume":"15","author":"P Alex","year":"2009","unstructured":"Alex, P. et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 15, 341\u2013352 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"10015_CR31","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/ibd.21557","volume":"17","author":"I Koboziev","year":"2011","unstructured":"Koboziev, I., Karlsson, F., Zhang, S. & Grisham, M. B. Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: Translating preclinical data into new drug therapies. Inflamm. Bowel Dis. 17, 1229\u20131245 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"10015_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fimmu.2019.00277","volume":"10","author":"D Parada Venegas","year":"2019","unstructured":"Parada Venegas, D. et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol. 10, 277 (2019).","journal-title":"Front. Immunol."},{"key":"10015_CR33","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1038\/s41467-020-18262-6","volume":"11","author":"W Yang","year":"2020","unstructured":"Yang, W. et al. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat. Commun. 11, 4457 (2020).","journal-title":"Nat. Commun."},{"key":"10015_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569\u2013573 (2013).","journal-title":"Science"},{"key":"10015_CR35","doi-asserted-by":"publisher","first-page":"19032","DOI":"10.1038\/srep19032","volume":"6","author":"A Agus","year":"2016","unstructured":"Agus, A. et al. Western diet induces a shift in microbiota composition enhancing susceptibility to adherent-invasive E. coli infection and intestinal inflammation. Sci. Rep. 6, 19032 (2016).","journal-title":"Sci. Rep."},{"key":"10015_CR36","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3389\/fmicb.2018.01274","volume":"9","author":"J Xu","year":"2018","unstructured":"Xu, J. et al. 5-Aminosalicylic acid alters the gut bacterial microbiota in patients with ulcerative colitis. Front. Microbiol. 9, 1274 (2018).","journal-title":"Front. Microbiol."},{"key":"10015_CR37","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/microorganisms9061252","volume":"9","author":"G D\u00e9jean","year":"2021","unstructured":"D\u00e9jean, G. et al. Identifying a novel bile salt hydrolase from the keystone gut bacterium Christensenella minuta. Microorganisms 9, 1252 (2021).","journal-title":"Microorganisms"},{"key":"10015_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fmed.2021.716266","volume":"8","author":"J-C Paquet","year":"2021","unstructured":"Paquet, J.-C. et al. Entering first-in-human clinical study with a single-strain live biotherapeutic product: Input and feedback gained from the EMA and the FDA. Front. Med. 8, 25 (2021).","journal-title":"Front. Med."},{"key":"10015_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40168-021-01206-7","volume":"10","author":"S Bellais","year":"2022","unstructured":"Bellais, S. et al. Species-targeted sorting and cultivation of commensal bacteria from the gut microbiome using flow cytometry under anaerobic conditions. Microbiome 10, 1 (2022).","journal-title":"Microbiome"},{"key":"10015_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nmicrobiol.2016.203","volume":"1","author":"J-C Lagier","year":"2016","unstructured":"Lagier, J.-C. et al. Culture of previously uncultured members of the human gut microbiota by culturomics. Nat. Microbiol. 1, 1\u20138 (2016).","journal-title":"Nat. Microbiol."},{"key":"10015_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1741-7007-11-61","volume":"11","author":"L Wrzosek","year":"2013","unstructured":"Wrzosek, L. et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 11, 61 (2013).","journal-title":"BMC Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10015-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10015-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10015-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:31:22Z","timestamp":1669339882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10015-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10015"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10015-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.R., K.L.C., C.K., D.K., G.D., L.B., C.M., G.R., F.E., W.M. and S.P.C. were employees of Ysopia Bioscience during the conduct of the study. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6017"}}